Literature DB >> 21440559

Multinomial model-based formulations of TCP and NTCP for radiotherapy treatment planning.

R Keinj1, T Bastogne, P Vallois.   

Abstract

Hit and target models of tumor growth, typically assume that all surviving cells have a constant and homogeneous sensitivity during the radiotherapy period. In this study, we propose a new multinomial model based on a discrete-time Markov chain, able to take into account cell repair, cell damage heterogeneity and cell proliferation. The proposed model relies on the 'Hit paradigm' and 'Target' theory in radiobiology and assumes that a cancer cell contains m targets which must be all deactivated to produce cell death. The surviving cell population is then split up into m categories to introduce the variation of cancer cell radio-sensitivity according to their damage states. New expressions of the Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP) are provided. Moreover, we show that hit and target models may be regarded as particular cases of the multinomial model. Numerical results should permit to keep the efficiency of treatment with a lower total radiation dose then that given by the typical hit models, which allow to decrease side effects.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21440559     DOI: 10.1016/j.jtbi.2011.03.025

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  2 in total

1.  The effect of setup uncertainty on optimal dosimetric margin in LINAC-based stereotactic radiosurgery with dynamic conformal arc technique.

Authors:  Xiaoyu Duan; William Giles; John P Kirkpatrick; Fang-Fang Yin
Journal:  J Radiosurg SBRT       Date:  2019

2.  In-vivo dose measurements with MOSFET dosimeters during MV portal imaging.

Authors:  Sathish Kumar; Rabi Raja Singh; Henry Finlay Godson; Retna Ponmalar; Paul Ravindran; Sunil Dutt Sharma; Subhashini John
Journal:  Rep Pract Oncol Radiother       Date:  2021-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.